London Co. of Virginia Has $19.88 Million Position in Haemonetics Corporation $HAE

London Co. of Virginia lifted its position in shares of Haemonetics Corporation (NYSE:HAE) by 33.9% in the first quarter, HoldingsChannel.com reports. The fund owned 352,807 shares of the medical instruments supplier’s stock after buying an additional 89,242 shares during the period. London Co. of Virginia’s holdings in Haemonetics were worth $19,884,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in HAE. AQR Capital Management LLC increased its stake in Haemonetics by 48.6% in the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after acquiring an additional 1,034,226 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Haemonetics by 994.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after purchasing an additional 1,254,035 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after purchasing an additional 233,119 shares during the last quarter. North Peak Capital Management LLC boosted its holdings in shares of Haemonetics by 204.4% in the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after purchasing an additional 740,626 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Haemonetics by 17.3% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock valued at $47,400,000 after purchasing an additional 124,020 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. JPMorgan Chase & Co. reduced their price objective on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Mizuho lifted their target price on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. BTIG Research reiterated a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a research report on Friday, June 26th. Finally, Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and a consensus target price of $78.89.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $78.56 on Friday. The company has a market cap of $3.57 billion, a P/E ratio of 38.89, a PEG ratio of 1.59 and a beta of 0.52. The business has a 50-day moving average price of $72.75 and a two-hundred day moving average price of $66.17. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts anticipate that Haemonetics Corporation will post 5.21 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.